Global In Vitro Toxicology Testing Market (Drivers, Restraints, Opportunities, Trends and Forecast) 2018-2024

  • Product Code:
  • Published Date:
    Mar 2019
  • Region:
  • Pages:
  • Category:
    Healthcare & Pharmaceuticals
  • Publisher:
    Infoholic Research
Global In Vitro Toxicology Testing Market – Drivers, Restraints, Opportunities, Trends, and Forecast: 2018–2024
Overview: In vitro toxicology involves the study of cells or tissues grown or maintained in precise lab conditions to observe the toxic properties of the compound. These testing methods help in inspecting the toxicity of xenobiotics at the cellular level in the laboratory without the interaction of complex physiological systemic effects that are often observed in living organisms. In vitro methods are commonly used in recent years as these can be correlated with in vivo studies and assist in understanding a particular in vivo response in any animal species. It is commonly employed by the pharmaceutical, chemical, food, cosmetic, medical device, and diagnostics industries to test the safety (toxicity) and efficacy of drugs, chemicals, biochemicals, materials, and preparations. Most of the information about the potential toxicity of drug substances are obtained from using animal models, but these tend to have significant limitations when translating them to human risk assessment. Although some basic toxicity testing using human cells in vitro is already a conventional method, many toxicologists are developing more sophisticated in vitro analyses using human-based cell models that can be more predictive about human health outcomes.
The market for in vitro toxicology testing is driven by high opposition to animal testing, increased cost related to animal-based toxicity testing, and increasing R&D expenditure for early stage toxicity testing. Whereas, the lack of in vitro models and decreased adoption rate are limiting the growth of the market to an extent.
Market Analysis: The “global in vitro toxicology testing market” is estimated to witness a CAGR of 8.2% during the forecast period 2018–2024. The global market is analyzed based on three segments – toxicology endpoints, industry type, and regions.
Regional Analysis: The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (ROW). Europe is the major shareholder in the global in vitro toxicology testing market, followed by North America. The upsurge in the investments by the European Commission in R&D to develop substitute methods to in vivo testing is driving the demand in this region. Asia Pacific is expected to grow at a high CAGR during the forecast period due to increasing number of contract research organizations offering testing services, advancements in healthcare infrastructure, increasing investments in the biopharmaceutical sector, and upward economic conditions in this region.
Toxicology Endpoints Analysis: The in vitro toxicology testing market, by toxicology endpoints, is segmented into systemic toxicity, cytotoxicity testing, genotoxicity testing, ocular toxicity, organ toxicity, dermal toxicity, neurotoxicity, and others. Among these, systemic toxicity accounted for the highest market share in 2017 due to the availability of a wide range of sub-studies, which ensure total analysis of toxicity and safety margin of the testing compounds.
Industry Type Analysis: The in vitro toxicology testing market, by industry type, is segmented into pharmaceutical and biopharmaceutical, cosmetics, chemical, diagnostics, and food industry. The pharmaceutical and biopharmaceutical industry occupied significant market share in 2017 and the cosmetics industry is expected to hold a higher percentage during the forecast period. Increased support of regulatory authorities to use in vitro and in silico methods instead of animal testing to check toxicology is driving the growth of the cosmetic industry.
Key Players:
Laboratory Corporation of America Holdings, Charles River Laboratories, Inc., Bio-Rad Laboratories, GE Healthcare, Thermo Fisher Scientific, Eurofins Scientific, SGS SA, BioIVT, Agilent Technologies, Inc., Abbott Laboratories, Gentronix Limited, Promega Corporation, MB Research Laboratories, Evotec AG (Cyprotex plc), Catalent, Inc., Qiagen N.V., and niche players.
Competitive Analysis: There is an increase in collaborations between companies on in vitro testing of compounds. For instance, in December 2016, Evotec and Celgene entered into a drug discovery collaboration for neurodegenerative diseases. According to agreement terms, Celgene will use Evotec's unique induced pluripotent stem cell (iPSC) platform that enables systematic drug screening in patient-derived disease models. In June 2017, Censo Biotechnologies Ltd. collaborated with Evotec AG to source and provide patient-derived induced pluripotent stem cells to support Evotec’s drug discovery iPSC platform. In addition, the companies are also coming up with new products for in vitro testing. For instance, in January 2018, STEMCELL Technologies Inc. released two product lines for organoid research that will enable scientists to create powerful models for studying human disease in the lab.
Benefits: The report provides complete details about the services offered by in vitro toxicology testing companies in various therapeutic verticals and regions. With that, key stakeholders can know about the major trends, drivers, investments, and vertical player’s initiatives. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.
Key Stakeholders:

Table of Contents
1.1 Industry overview 9
1.2 Importance of toxicology studies 10
2 Report Outline 11
2.1 Report Scope 11
2.2 Report Summary 11
2.3 Research Methodology 12
2.4 Report Assumptions 12
3 Market Snapshot 14
3.1 Market Definition – Infoholic Research 14
3.2 Advantages of In vitro testing 14
3.3 Segmented Addressable Market (SAM) 14
3.4 Trends of the in vitro toxicology testing market 15
3.5 Related Markets 16
3.5.1 In vivo toxicology 16
3.5.2 ADME Toxicology testing 16
3.5.3 Biologics safety testing 16
4 Market Outlook 18
4.1 Market segmentation 18
4.2 PEST Analysis 18
4.3 Porter 5(Five) Forces 19
5 Market Characteristics 21
5.1 DRO – Global In Vitro Toxicology Testing Market Dynamics 21
5.1.1 Drivers 21 High opposition to animal testing 21 Low cost associated with in vitro toxicology testing 22
5.1.2 Opportunities 22 Advent of new in vitro models 22 Upsurge in toxicology database will facilitate the use of in vitro testing methods 23
5.1.3 Restraints 24 Barriers in adopting in vitro testing methods 24 Deficiency of in vitro models to conduct complex studies 24
5.2 DRO – Impact Analysis 25
5.3 Key Stakeholders 26
6 Toxicity endpoints: Market Size and Analysis 28
6.1 Overview 28
6.2 Systemic toxicity testing 29
6.3 Cytotoxicity testing 29
6.4 Genotoxicity testing 29
6.5 Organ toxicity 30
6.6 Ocular toxicity 30
6.7 Dermal toxicity 30
6.8 Neurotoxicity 31
6.9 Others 31
7 Industry type: Market Size and Analysis 32
7.1 Overview 32
7.2 Pharma and biopharma industry 33
7.3 Cosmetics industry 34
7.4 Chemical industry 35
7.5 Food industry 36
7.6 Diagnostics industry 37
8 Regions: Market Size and Analysis 39
8.1 Overview 39
8.2 North America 40
8.3 Europe 41
8.4 Asia Pacific 42
8.5 Rest of the World 44
9 Competitive Landscape 45
9.1 Overview 45
10 Vendor Profiles 47
10.1 Laboratory Corporation of America Holdings (LABCORP) 47
10.1.1 Overview 47
10.1.2 Laboratory Corporation of America Holdings: Recent Developments 48
10.1.3 Business Units 51
10.1.4 Geographic Revenue 52
10.1.5 Business Focus 52
10.1.6 SWOT Analysis 53
10.1.7 Business Strategies 53
10.2 Charles River Laboratories, Inc. 54
10.2.1 Overview 54
10.2.2 Charles River Laboratories, Inc.: Recent Developments 56
10.2.3 Business Units 59
10.2.4 Geographic Revenue 59
10.2.5 Business Focus 60
10.2.6 SWOT Analysis 61
10.2.7 Business Strategies 61
10.3 Thermo Fisher Scientific, Inc. 62
10.3.1 Overview 62
10.3.2 Business Units 67
10.3.3 Geographic Revenue 68
10.3.4 Business focus 69
10.3.5 SWOT analysis 70
10.3.6 Business Strategy 70
10.4 Eurofins Scientific 71
10.4.1 Overview 71
10.4.2 Geographic Revenue 74
10.4.3 Business focus 75
10.4.4 SWOT analysis 75
10.4.5 Business Strategy 76
10.5 Agilent Technologies Inc. 77
10.5.1 Overview 77
10.5.2 Business Units 81
10.5.3 Geographic Revenue 82
10.5.4 Business Focus 83
10.5.5 SWOT Analysis 84
10.5.6 Business Strategies 84
11 Companies to Watch For 86
11.1 SGS SA 86
11.1.1 Overview 86
11.2 Abbott Laboratories 88
11.2.1 Overview 88
11.3 GE Healthcare 90
11.3.1 Overview 90
11.4 BioReliance Corporation (a subsidiary of Merck KGaA) 93
11.4.1 Overview 93
11.5 BioIVT 94
11.5.1 Overview 94
11.6 Bio-Rad Laboratories 96
11.6.1 Overview 96
11.6.2 Bio-Rad Laboratories: Recent Developments 97
11.7 Catalent, Inc. 98
11.7.1 Overview 98
11.7.2 Catalent Inc: Recent Developments 98
11.8 Evotec AG (Cyprotex plc) 100
11.8.1 Overview 100
11.8.2 Evotec AG: Recent Developments 101
11.9 Gentronix Limited 104
11.9.1 Overview 104
11.9.2 Gentronix Limited: Recent Developments 104
11.10 Promega Corporation 105
11.10.1 Overview 105
11.10.2 Promega Corporation: Recent Developments 106
11.11 Qiagen N.V. 106
11.11.1 Overview 106
12 Annexure 111
12.1 Abbreviations 111

Please enter your personal details below
I want to buy this report
I am willing to know the scope of research
I have customized query over this report
America Holdings, Charles River Laboratories, Inc., Bio-Rad Laboratories, GE Healthcare, Thermo Fisher Scientific, Eurofins Scientific, SGS SA, BioIVT, Agilent Technologies, Inc., Abbott Laboratories, Gentronix Limited, Promega Corporation, MB Research Laboratories, Evotec AG (Cyprotex plc), Catalent, Inc., Qiagen N.V., and niche players.
Please enter your personal details below
I want to buy this report
I am willing to know the scope of research
I have customized query over this report

Related Reports